MT1 vs MT2: Melanotan 1 and Melanotan 2 Compared

The difference everything else follows from: receptor selectivity

Both compounds are analogs of alpha-melanocyte-stimulating hormone (alpha-MSH), the natural hormone that regulates pigment. They differ in how narrowly they act.

Melanotan 1 is a linear alpha-MSH analog with two substitutions (Nle at position 4 and D-Phe at position 7) that make it more stable and longer-acting than the natural hormone. It leans toward the melanocortin-1 receptor. MC1R is a Gs-protein-coupled receptor: when an agonist such as alpha-MSH or afamelanotide binds it, the cell raises its cyclic AMP signal, which shifts melanogenesis toward eumelanin, the darker pigment that absorbs and scatters UV light (Herraiz et al., 2021, Pigment Cell Melanoma Res).

Melanotan 2 is a cyclic, shortened analog and is non-selective, acting at MC1R, MC3R, MC4R and MC5R. Receptor focus is what separates the family: MC1R governs pigment, MC4R is linked to appetite and sexual function, and MC3R and MC5R have other roles. That is the mechanistic reason reports of melanotan 2 describe effects beyond tanning while melanotan 1 is documented mainly for pigment.

What published research reports on the tanning response

For melanotan 1, added pigment is not a side effect of the approved use, it is the point of it. Afamelanotide is approved for adults with erythropoietic protoporphyria (EPP), a rare inherited condition in which sunlight triggers skin pain, and the eumelanin the compound raises is the basis for that approved use (FDA approval, 2019). The pigment pathway itself is the MC1R signaling described above (Herraiz et al., 2021).

For melanotan 2, the pigmentation reports are the reason the compound is known at all, but they sit on a much thinner record. Melanotan 2 has not been through a registered program comparable to the one behind afamelanotide, so there is no approved labeling to quote and no trial dataset that puts a number on how much pigment change to expect or how quickly. Our own melanotan 2 material describes the peptide as priming the skin to produce more melanin, with a light stimulus still required to trigger the response, which means exposure is part of any outcome rather than something the compound removes.

We have no head-to-head study of the two compounds to cite, so nothing here should be read as one being a stronger tanning agent than the other. What can be said from the record is narrower and more useful: one has an approved use built on the pigment it produces, and the other has reports without a program behind them.

Reported side-effect profiles, kept apart on purpose

These two lists are not the same kind of object. One is an approved adverse-reaction list. The other is a set of commonly reported effects with no registered trial program quantifying them. Presenting them in a single merged column would imply an equivalence that does not exist, so they stay in separate cards.

One class-level reference point does exist, and it is worth reading precisely. PT-141 (bremelanotide) is chemically derived from melanotan 2 and went through a phase 3 program: nausea was reported in about 40 percent of participants, alongside flushing, headache, and transient rises in blood pressure with small decreases in heart rate (Kingsberg et al., 2019). The approved labeling for the same compound separately records focal hyperpigmentation with more frequent dosing (Vyleesi prescribing information). Those are bremelanotide numbers. They describe what the melanocortin class can do, not what melanotan 2 does at any particular amount, and they are not a substitute for data melanotan 2 does not have.

Both compounds are reported to darken moles. The approved afamelanotide labeling recommends a full-body skin examination twice a year for that reason (FDA approval, 2019), and our own melanotan 2 material treats documenting moles before first use as non-negotiable and states that anyone with a personal or family history of melanoma or atypical moles should not use it and should see a dermatologist.

Which research contexts each one appears in

MT1 vs MT2 at a glance

No column in this table wins. Where melanotan 2 has no comparable source, the cell says so instead of leaving a gap that would read as nothing to report.

The 16 mg implant figure is the approved product specification for afamelanotide, not a dose an individual selects, and it has no counterpart on the melanotan 2 side because no approved dose exists there.

What this comparison cannot tell you

Three limits are worth stating outright, because a tidy table hides them well.

• There is no head-to-head trial. Everything above compares two separate records, one of them much thinner than the other.
• Neither is approved for cosmetic tanning. The afamelanotide approval covers EPP only, and melanotan 2 has no approval at all, so the cosmetic use that drives most of the interest in both compounds is the use with the least data behind it.
• Limited data is not a safety finding. The absence of quantified adverse events for melanotan 2 reflects the absence of a program that would have counted them, and reads as a gap rather than as reassurance.

Reading further on each compound

Each compound has its own page here, with the full detail this comparison compresses.